Welcome to our dedicated page for NCR Atleos SEC filings (Ticker: NATL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading NCR Atleos Corp’s multi-segment disclosures can feel like decoding a network protocol—hardware margins, software subscriptions, and Allpoint transaction fees are scattered across hundreds of pages. If finding NCR Atleos insider trading Form 4 transactions or the latest NCR Atleos quarterly earnings report 10-Q filing is taking too much time, you’re not alone.
Stock Titan’s AI distills every submission the moment it hits EDGAR. Our platform links each form to the question it answers:
- 10-K—see a NCR Atleos annual report 10-K simplified with segment revenue, ATM deployment counts, and cybersecurity risks.
- 10-Q—get concise NCR Atleos earnings report filing analysis plus quarter-over-quarter hardware backlog trends.
- Form 4—track NCR Atleos Form 4 insider transactions real-time and understand executive stock movements.
- 8-K—new product launches or outages? View NCR Atleos 8-K material events explained in plain language.
- DEF 14A—dig into the NCR Atleos proxy statement executive compensation table without scrolling for hours.
Whether you’re comparing ATM refresh cap-ex, monitoring NCR Atleos executive stock transactions Form 4, or simply understanding NCR Atleos SEC documents with AI, we surface what matters: cash flow by segment, service contract backlog, and network fee growth. Real-time alerts, AI-powered summaries, and clear tagging mean you spend minutes—not evenings—on due diligence, confident you’ve captured every disclosure that can move the stock.
Form 4 overview: Director Laura Berner of Bolt Biotherapeutics (BOLT) reported a single equity-based transaction dated May 27 2025. She received a non-qualified stock option for 1,100 common shares at an exercise price of $6.40 per share. All figures give effect to the 1-for-20 reverse stock split that the company executed on June 6 2025.
Key terms of the grant:
- Vesting: Options vest on the earlier of May 27 2026 or the day immediately prior to the next annual meeting, subject to continued service.
- Change-in-control: The award vests in full upon a change-in-control event.
- Expiration: May 26 2035 (10-year life).
No shares were purchased or sold; the filing reflects compensation-related option issuance. Post-grant, Berner beneficially owns 1,100 derivative securities and no disclosed non-derivative common shares.
Corporate context: The recent reverse split consolidated each 20 common shares into one, reducing the share count and proportionally increasing exercise prices. Prior to the split, the grant was for 22,000 shares at $0.32 per share. The filing provides no additional financial or operational data.
FAQ
What is the current stock price of NCR Atleos (NATL)?
What is the market cap of NCR Atleos (NATL)?
What is the core business of NCR Atleos Corp?
How does NCR Atleos Corp generate its revenue?
What are the main segments of NCR Atleos Corp's operations?
How does NCR Atleos Corp differentiate itself in the fintech market?
Who are the primary customers of NCR Atleos Corp?
What technological innovations does the company employ?
How does the integrated solution enhance banking operations?
How does NCR Atleos Corp address security and operational efficiency?
